[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658172":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":11,"studyPopulation":11,"armGroups":24,"interventions":37,"overallOfficials":11,"centralContacts":51,"locations":56,"responsibleParty":74,"collaborators":11,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":11,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":11,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)",null,"Up to 4 days.",{"measure":14,"description":11,"timeFrame":12},"Maximum measured concentration of the analyte in plasma (Cmax)",[16],{"measure":17,"description":11,"timeFrame":12},"Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)",{"allocation":19,"interventionModel":20,"interventionModelDescription":11,"primaryPurpose":21,"observationalModel":11,"timePerspective":11,"maskingInfo":22},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":23,"maskingDescription":11,"whoMasked":11},"NONE",[25,33],{"label":26,"type":27,"description":28,"interventionNames":29},"Reference treatment (R), then Test treatment (T)","EXPERIMENTAL","Vicadrostat + empagliflozin administered at the same time (R), then Vicadrostat + empagliflozin combined (T)",[30,31,32],"Drug: Vicadrostat","Drug: Empagliflozin","Drug: Vicadrostat + empagliflozin",{"label":34,"type":27,"description":35,"interventionNames":36},"Test treatment (T), Reference treatment (R)","Vicadrostat + empagliflozin combined (T), then Vicadrostat + empagliflozin administered at the same time (R)",[30,31,32],[38,42,47],{"type":39,"name":40,"description":40,"armGroupLabels":41,"otherNames":11},"DRUG","Vicadrostat",[26,34],{"type":39,"name":43,"description":43,"armGroupLabels":44,"otherNames":45},"Empagliflozin",[26,34],[46],"Jardiance®",{"type":39,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"Vicadrostat + empagliflozin","Vicadrostat + empagliflozin combined",[26,34],[52],{"name":5,"role":53,"phone":54,"phoneExt":11,"email":55},"CONTACT","1-800-243-0127","clintriage.rdg@boehringer-ingelheim.com",[57],{"facility":58,"status":59,"city":60,"state":11,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Humanpharmakologisches Zentrum Biberach","RECRUITING","Biberach","88397","Germany","DE",{"type":65,"coordinates":66},"Point",[67,68],8.03333,48.33333,{"lat":68,"lon":67},[71],{"name":5,"role":53,"phone":72,"phoneExt":11,"email":73},"08007234742","deutschland@bitrialsupport.com",{"type":75,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100658172","phase-1-a-study-in-healthy-people-to-compare-how-2-different-formulations-of-vicadrostat--empagliflozin-tablets-are-taken-up-in-the-body-100658172",false,"NCT07845630","A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat \u002F Empagliflozin Tablets Are Taken up in the Body","Bioequivalence of Two Different Vicadrostat \u002F Empagliflozin Formulations Following Oral Administration in Healthy Trial Participants (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)","Inclusion Criteria:\n\n1. Healthy male or female trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure, Pulse rate), 12-lead Electrocardiogram, and clinical laboratory tests\n2. Age of 18 to 55 years (inclusive)\n3. Body mass index of 18.5 to 29.9 kg \u002F m\\^2 (inclusive)\n4. Signed and dated written informed consent in accordance with International Council for Harmonisation - Good Clinical Practice and local legislation prior to admission to the trial\n5. Further inclusion criteria apply.\n\nExclusion Criteria:\n\n1. Any finding in the medical examination (including Blood pressure, Pulse rate or Electrocardiogram) deviating from normal and assessed as clinically relevant by the investigator\n2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm\n3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance\n4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator\n5. Further exclusion criteria apply.",true,"ALL","18 Years","55 Years",{"count":88,"type":89},36,"ESTIMATED","INTERVENTIONAL",[92],"PHASE1","The main objective of this trial is to establish the bioequivalence of two different formulations of vicadrostat \u002F empagliflozin in healthy male and female trial participants following oral administration.",[95],"Healthy","2026-10-14",{"date":98,"type":99},"2026-10-15","ACTUAL",{"date":96,"type":89},{"date":102,"type":89},"2026-12-21",{"name":5,"class":6},1]